AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06298929 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: medial rectus fenestration
Description: Fenestration technique involves making two splitting incisions by blunt dissection parallel to the muscle fibers on the superior and inferior borders of the muscle, leaving 1 mm of muscle fibers on each edge. The rectangular wide central part is excised from the insertion and between the two splitting incisions to a point back 5-8 mm depending on the angle of the esotropia.
Study NCT06298929 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: medial rectus recession
Description: recession is one of the gold standard weakening procedures that involves disinsertion of the muscle and re-suturing to the sclera at a more posterior location to decrease its contractile power.
Study NCT05075265 — intervention group
Intervention type: DRUG
Intervention: Methadone
Description: Standard dose of 0.2 ug/kg before Cardiopulmonary Bypass.
Study NCT05764525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVZ-149 Injections
Description: IV infusion of 1000 mg of VVZ-149
Study NCT05764525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion of 0 mg of VVZ-149
Study NCT06446817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LuxHighAdd IOL
Description: Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.
Study NCT06446817 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LuxGood IOL
Description: Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.
Study NCT05041413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moms Quit
Description: Participants will receive text messages tailored on (1) current smoking status and (2) intention to quit/remain quit. Message content includes supportive messaging for child and self-care, relapse prevention, and smoking cessation. Women who are ready to quit will receive messages from the SmokeFreeText library.
Study NCT05041413 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text4Baby
Description: Text4Baby is a free, publicly available text messaging program that provides information about nutrition, safe sleep tips, baby's milestones, signs and symptoms of labor, doctor visit and appointment reminders, breastfeeding advice, car seat safety, information on health insurance, urgent health alerts, and resource hotlines and websites.
Study NCT05362656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VX1+ dispersion mapping
Description: Careful biatrial high density dispersion mapping is performed as the first step of the procedure. Operators map each region of both atria carefully by moving the mapping catheter slowly. If VX1+ application detects dispersion regions, the corresponding dipoles location will be automatically tagged on the 3D-map. Accuracy and relevance of dispersion regions should be confirmed by the operator by checking EGMs visually.
Study NCT04609956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Virtual reality consists of a headphones, a virtual reality headset and a smartphone.
Study NCT04609956 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard
Description: Standard arm is the habitual procedure. They use hydroxyzine and music with headphones
Study NCT04983017 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplement
Description: iron bisglycinate manganese chloride vitamin D2 guar gum indole-3-carbinol L-methionine piceatannol biotin caffeine beta-carotene lutein zinc sulfate
Study NCT04983017 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched Placebo to Intervention
Study NCT05876078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doraya catheter
Description: Temporary deployment of the Doraya catheter in ADHF patients
Study NCT04950127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linerixibat
Description: Participants will receive linerixibat.
Study NCT04950127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo.
Study NCT04950127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo.
Study NCT05537883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Patients receiving the intervention will undergo Transversus Abdominis Plane (TAP) block with liposomal bupivacaine
Study NCT05537883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Injection
Description: Patients receiving the intervention will undergo Transversus Abdominis Plane (TAP) block with plain bupivacaine
Study NCT05590377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modakafusp Alfa
Description: Modakafusp alfa intravenous infusion
Study NCT05590377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab SC injection
Study NCT04789603 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6-min-walk surgical mask
Description: To walk as fast as possible without running for 6 minutes with surgical mask
Study NCT04789603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6-min-walk Fpp2
Description: To walk as fast as possible without running for 6 minutes with Fpp2 mask
Study NCT04789603 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6-min-walk without mask
Description: To walk as fast as possible without running for 6 minutes without mask
Study NCT06253988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Formula
Description: intra-pocket formula (local delivery drug)
Study NCT06253988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo formula
Description: intra-pocket formula (local delivery drug)
Study NCT05449821 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum and salivary samples will be collected. Asprosin levels will be determined by biochemical analysis
Description: Serum and saliva samples will be collected from both groups for biochemical analysis.
Study NCT06223867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jaspr App + JAH
Description: With assistance form a research coordinator, the subject will complete self-administered suicide risk assessment on the tablet via Jaspr app, then the subject will engage with suicide-related coping skills and resources that the app provides. Subject will continue to have access to the coping skills and videos via a mobile app after discharge.
Study NCT06223867 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ETAU
Description: Usual care for suicidal patients at UMass Memorial ED that may include Behavioral health evaluation by a trained clinician. Environmental safety precautions. Personalized safety upon discharge
Study NCT06223867 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ETAU
Description: Usual care for suicidal patients at UMass Memorial ED that may include Behavioral health evaluation by a trained clinician. Environmental safety precautions. Personalized safety upon discharge
Study NCT05595148 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate WBAT
Description: Men or women over 18 years who present with a fracture of the acetabulum, pelvis, distal femur, proximal tibia, distal tibia, who will undergo fracture fixation within 7 days of their injury and consent to the research study.
Study NCT05595148 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention: Delayed WBAT
Description: Patients with ankle fractures will be instructed to touch-down (toe touch or foot flat) weight bear (approximately 10% of body weight) while in the boot for. Patients will be instructed to keep foot off of floor or set ball of foot or heal on ground for balance using walker or crutches at all times. After the 6 week post op visit, patients may begin weight bearing as tolerated. Patients with tibial plateau fractures will be instructed to touch down (toe touch or foot flat) weight bear (approximately 10% of body weight) for at least 6 weeks. After the 6 week post op visit, patients may begin weight bearing as tolerated until full weight bearing is achieved.
Study NCT05446649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling
Description: the patient will be in comfortable position .and clean the area over upper trapezius and sub occipital muscles. detect the trigger point then Perpendicular needling into the bulk of the muscle is the safest technique for this area.
Study NCT05446649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: instrumented assisted soft tissue mobilization
Description: the patients will be in sitting position. The appropriate IASTM technique instrument will be selected to scan, and then treat the affected area for 30 to 60 seconds per treated area. The procedure will be applied to the superficial cervical fascia and investing the layers of deep cervical fascia that surround all the structures in the neck. Strokes will be applied on the sub occipital and upper fibers of trapezius muscle. The IASTM technique will be applied at a 45° angle in a direction parallel to the treated muscle fibers for 20 seconds, followed immediately by an additional 20 seconds application at a 45° angle in a perpendicular direction to the muscle fibers, resulting in a total treatment time of approximately 40 seconds. The patients will be advised that they might be sore, bruised, or have small red dots called petechiae, on the treated area. Ice will be applied for 15 to 20 min after the treatment if there will be a massive soreness.
Study NCT05446649 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: patients will be received traditional physiotherapy (stretching and strengthening cervical muscles and postural correction exercise)
Study NCT05446649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: patients will be received traditional physiotherapy (stretching and strengthening cervical muscles and postural correction exercise)
Study NCT05386043 — intervention group
Intervention type: DRUG
Intervention: FET F-18
Description: PET scan with FET prior to biopsy
Study NCT05386043 — intervention group
Intervention type: DRUG
Intervention: O-15 Radioisotope
Description: PET scan with O-15 Water prior to biopsy
Study NCT05386043 — intervention group
Intervention type: PROCEDURE
Intervention: CT scan
Description: CT scan prior to biopsy
Study NCT05386043 — intervention group
Intervention type: PROCEDURE
Intervention: MRI with gadolinium-based contrast
Description: MRI prior to biopsy
Study NCT05386043 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsy Collection
Description: Biopsy collection during standard of care neurosurgery for glioma diagnosis/excision
Study NCT06499844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: acetylcholine, and acetylcholine + L-NAME (Nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelium- and nitric oxide-dependent dilation
Study NCT06501001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Description: Three weekly, supervised exercise sessions with high intensity. Each session will last for 45 minutes. The intervention period will be sixteen weeks.
Study NCT06501001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Time-Restricted Eating
Description: Restricted daily window of caloric intake to a maximum 10 hours. The intervention period will be sixteen weeks.
Study NCT06052761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Making Toys from Medical Materials
Description: Rabbit Making: The two fingers and the palm of the medical glove will be filled with cotton and the bottom part will be tied. The finger part of the glove will form the rabbit's ears, and the palm part will form its face. After the glove is shaped, the rabbit's eyes and mouth will be drawn with a pencil.~Cat Making: Three abeslangs will be cut to appropriate sizes to create the cat. The cut pieces will be combined to form the cat's head, feet, and tail. After the assembly process is completed, the cat's eyes, nose and beard will be drawn with a pencil.~Plane Making: The 10 cc syringe and needle tip removed from its packaging will be combined. Children will be asked to color the two abeslangs given to them in the color they want. The abeslangs painted by the children will be fixed to the syringe with a plaster, one on the bottom and the other on the top.
Study NCT06245889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: chemotherapy
Study NCT06245889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: chemotherapy
Study NCT06245889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: immunotherapy
Study NCT06245889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: additional chemotherapy - neoadjuvant or adjuvant rescue
Study NCT06245889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: additional chemotherapy - adjuvant rescue
Study NCT06245889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: adjuvant rescue
Study NCT06245889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: adjuvant rescue
Study NCT04855916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABLE Exoskeleton
Description: Participants will use the ABLE Exoskeleton to perform therapy activities (sit-to-stand transfers, walk, turns, balance exercises, normalized tests). Participants will perform a total of 10 training sessions of an approximate duration of 90 minutes.
Study NCT04855916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KAFO Orthosis
Description: Participants will use a pair of KAFO-type passive orthosis to perform therapy activities (sit-to-stand transfers, walk, turns, balance exercises, normalized tests). Participants will perform a total of 10 training sessions of an approximate duration of 90 minutes.
Study NCT04921241 — intervention group
Intervention type: OTHER
Intervention: In Utero Exposure to SARS-CoV-2
Description: Born to mother with SARS-CoV-2 infection during pregnancy
Study NCT06018337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1303/BNT323
Description: IV
Study NCT06018337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Oral
Study NCT06018337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV
Study NCT06018337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: IV
Study NCT06317181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collection of elastography data
Description: patients who are scheduled for an elastography for clinical reasons usually receive an ultrasound scan in which the b-mode images of the liver tissue are collected. In this study additional radiofrequency data is collected through a software access.
Study NCT06317181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collection of ultrasonic raw data
Description: Patients who are transferred to the ultrasound departement due to suspicious focal lesions receive an ultrasonic investigation including the acquisition of raw data and extracting a definitive diagnose from the following clinical routine investigation, depending on the standards of the participating center
Study NCT04272294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Spectroscopy
Description: Using oral spectroscopy device to characterize treatment response in tumors
Study NCT04974671 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: 1-5 fraction Stereotactic Body Radiation Therapy to all sites of progression
Study NCT05897541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-217622
Description: Administered as a tablet.
Study NCT05897541 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as a tablet.
Study NCT06529536 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Genotyping for CYP3A4 and CYP3A5 genes
Description: Genotyping: Patients in the prospective (intervention) arm will undergo genotyping using Illumina's genome-wide genotyping array (Infinium Global Screening Array).~The determined diplotypes for CYP3A5 will be matched with predicted phenotypes using the Clinical Pharmacogenetics Implementation Consortium (CPIC®) proposed genotype-to-phenotype translation table. The assignment of the phenotype is outlined in the CPIC guidelines which will used to predict initial dose of tacrolimus.
Study NCT06529536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of NextDose platform
Description: NextDose platform is a forecasting tool used to predict tacrolimus dosage. It is a freely available tool and will be used in accordance with guideline. The dosing recommendations will be led by the academic pharmacist in consultation with the PI. This tool will use genotype-informed Bayesian dosing to help predict the time course of tacrolimus concentrations in the body.
Study NCT06529536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus is administered to all patients post SOT at RCH
Study NCT05958251 — intervention group
Intervention type: OTHER
Intervention: Cicaben
Description: Cicaben® powder is an association of special active ingredients for topical dermatological use with a healing, soothing and protective action (zinc oxide, magnesium oxide, corn starch, arnica montana extract, allantoin and undecylenic acid, arginine, glycine and proline, niacinamide).
Study NCT05958251 — intervention group
Intervention type: OTHER
Intervention: Standard Care (in control arm)
Description: Standard care
Study NCT05178173 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Sterile Water
Description: Sterile Water Placebo Comparator
Study NCT05178173 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 27% Ethanol plus essential oils
Description: Over-the-counter antiseptic mouth rinse
Study NCT05178173 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.075% Cetylpyridinium Chloride
Description: Over-the-counter antiseptic mouth rinse
Study NCT05968820 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Health Enhancement Intervention
Description: The program is based on principles from CBT-I (time in bed restriction, stimulus control, relaxation techniques, sleep education) and includes behavioral strategies to entrain circadian rhythm, strengthen sleep homeostasis, reduce hyperarousal, and sleep hygiene techniques. Self-Determination Theory (SDT) and Social Cognitive Theory (SCT) will serve as the theoretic framework for behavior change techniques (BCT) threaded through the sleep health enhancement intervention. Participants will maintain a sleep diary during the program to aid in tailoring the program, self-monitoring of behavior, and feedback of behavior. Goals will be set by the participant at each session and reviewed at subsequent sessions, and motivational interviewing principles will be incorporated.
Study NCT05720897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory Alone
Description: Participants randomized to this arm will receive earphones to listen to an 8 minute guided brief relaxation recording, focusing on breathing and a body scan. Participants will listen to the recording prior to their dental procedure.
Study NCT05720897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Relaxation Virtual Reality
Description: Participants randomized to this arm will receive will receive virtual reality goggles and choose a scene of their liking to experience. Participants will choose from 11 different themed environments (such as savannah, beach, meadow, or space), and will experience the chosen virtual reality environment for 8 minutes. Participants will complete the virtual reality intervention prior to their dental procedure.
Study NCT05109364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terazosin therapy
Description: Primary procedures in this study are MIBG scan, DAT scan, NM-MRI, and terazosin titration. Subjects will return for research visits and imaging every six months for three years. The investigators hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the a1- Adrenergic Receptor Antagonist Terazosin, resulting in a decreased clinical conversion rate to parkinsonism.
Study NCT04930445 — intervention group
Intervention type: DRUG
Intervention: Oxbryta® (voxelotor) 500mg Tablets
Description: Participants will receive treatment with Oxbryta as prescribed by their physician, as part of their usual care. Participants will be treated and evaluated per standard of care (SOC) and at the physician's discretion. There are no pre-defined treatment requirements.
Study NCT05913882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Strength Training (LVR+EMST)
Description: Combined respiratory muscle strength training regimen that will be completed daily for 5 weeks.
Study NCT05430854 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daxdilimab
Description: Daxdilimab will be administered subcutaneously as two injections for each dose.